The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Th. den Boer, A.
Right arrow Articles by Toes, R. E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Th. den Boer, A.
Right arrow Articles by Toes, R. E. M.
The Journal of Immunology, 2001, 167: 2522-2528.
Copyright © 2001 by The American Association of Immunologists

Longevity of Antigen Presentation and Activation Status of APC Are Decisive Factors in the Balance Between CTL Immunity Versus Tolerance1

Annemieke Th. den Boer2,3,*, Linda Diehl3,*, Geertje J. D. van Mierlo*, Ellen I. H. van der Voort*, Marieke F. Fransen*, Paul Krimpenfort{ddagger}, Cornelis J. M. Melief*, Rienk Offringa* and René E. M. Toes*,{dagger}

Departments of * Immunohematology and Blood Transfusion and {dagger} Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; and {ddagger} Divisions of Immunology, Cellular Biochemistry, and Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Encounter of Ag by naive T cells can lead to T cell priming as well as tolerance. The balance between immunity and tolerance is controlled by the conditions of Ag encounter and the activation status of the APC. We have investigated the rules that govern this balance in case an environment that normally induces tolerance is reverted into a milieu that promotes T cell priming, using a minimal CTL epitope derived from human adenovirus type 5 E1A. Vaccination of mice s.c. with E1A peptide in IFA readily induces CTL tolerance, resulting in the inability to control E1A-expressing tumors. The present study shows that efficient CTL priming is achieved when this peptide vaccine is combined with systemic administration of APC-activating compounds like agonistic anti-CD40 mAb or polyriboinosinate-polyribocytidylate. Surprisingly, this CTL response is not long-lasting and therefore fails to protect against tumor outgrowth. Disappearance of CTL reactivity was strongly associated with systemic persistence of the peptide for >200 days. In contrast, peptide administered in PBS does not persist and generates long term CTL immunity capable of rejecting Ad5E1A-positive tumors, when combined with CD40 triggering. Thus, presentation of CTL epitopes in an appropriate costimulatory setting by activated APC, although being essential and sufficient for CTL priming, eventually results in tolerance when the Ag persists systemically for prolonged times. These observations are important for the development of immune intervention schemes in autoimmunity and cancer.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. S. Bijker, S. J. F. van den Eeden, K. L. Franken, C. J. M. Melief, R. Offringa, and S. H. van der Burg
CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity
J. Immunol., October 15, 2007; 179(8): 5033 - 5040.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. de Witte, M. Toebes, J.-Y. Song, M. C. Wolkers, and T. N. M. Schumacher
Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease
Blood, May 1, 2007; 109(9): 3830 - 3838.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Bartholdy, S. O. Kauffmann, J. P. Christensen, and A. R. Thomsen
Agonistic Anti-CD40 Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Choriomeningitis Virus
J. Immunol., February 1, 2007; 178(3): 1662 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. E. Hamilton-Williams, A. Lang, D. Benke, G. M. Davey, K.-H. Wiesmuller, and C. Kurts
Cutting Edge: TLR Ligands Are Not Sufficient to Break Cross-Tolerance to Self-Antigens
J. Immunol., February 1, 2005; 174(3): 1159 - 1163.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Th. den Boer, G. J. D. van Mierlo, M. F. Fransen, C. J. M. Melief, R. Offringa, and R. E. M. Toes
The Tumoricidal Activity of Memory CD8+ T Cells Is Hampered by Persistent Systemic Antigen, but Full Functional Capacity Is Regained in an Antigen-Free Environment
J. Immunol., May 15, 2004; 172(10): 6074 - 6079.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Bronte, S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, C. De Santo, B. Macino, O. Marin, and P. Zanovello
Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase
J. Immunol., December 15, 2003; 171(12): 6396 - 6405.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
N. Haicheur, F. Benchetrit, M. Amessou, C. Leclerc, T. Falguieres, C. Fayolle, E. Bismuth, W. H. Fridman, L. Johannes, and E. Tartour
The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization
Int. Immunol., October 1, 2003; 15(10): 1161 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Mehrotra, R. Stevens, R. Zengou, N. G. Chakraborty, L. H. Butterfield, J. S. Economou, D. I. Dorsky, and B. Mukherji
Regulation of Melanoma Epitope-specific Cytolytic T Lymphocyte Response by Immature and Activated Dendritic Cells, in Vitro
Cancer Res., September 1, 2003; 63(17): 5607 - 5614.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Stober, I. Jomantaite, R. Schirmbeck, and J. Reimann
NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo
J. Immunol., March 1, 2003; 170(5): 2540 - 2548.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Cremer, M.-C. Dieu-Nosjean, S. Marechal, C. Dezutter-Dambuyant, S. Goddard, D. Adams, N. Winter, C. Menetrier-Caux, C. Sautes-Fridman, W. H. Fridman, et al.
Long-lived immature dendritic cells mediated by TRANCE-RANK interaction
Blood, November 15, 2002; 100(10): 3646 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
N. N. Kristensen, J. P. Christensen, and A. R. Thomsen
High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development
J. Gen. Virol., September 1, 2002; 83(9): 2123 - 2133.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. D. Higgins, M. A. Mihalyo, P. W. McGary, and A. J. Adler
CD4 Cell Priming and Tolerization Are Differentially Programmed by APCs upon Initial Engagement
J. Immunol., June 1, 2002; 168(11): 5573 - 5581.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Roth, J. Schwartzkopff, and H. Pircher
CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology
J. Immunol., May 15, 2002; 168(10): 5124 - 5129.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi
Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance
J. Exp. Med., February 11, 2002; 195(4): 423 - 435.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.